SCNI
Income statement / Annual
Last year (2025), Scinai Immunotherapeutics Ltd's total revenue was $1.31 M,
an increase of 99.24% from the previous year.
In 2025, Scinai Immunotherapeutics Ltd's net income was -$8.31 M.
See Scinai Immunotherapeutics Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$1.31 M |
$658.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$3.96 M
|
$1.24 M
|
$512.68 K
|
$559.80 K
|
$747.65 K
|
$708.92 K
|
$461.69 K
|
$72.32 K
|
$123.55 K
|
$0.00
|
| Gross Profit |
-$2.65 M
|
-$580.00 K
|
-$512.68 K
|
-$559.80 K
|
-$747.65 K
|
-$708.92 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
-2.02
|
-0.88
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$2.37 M
|
$5.53 M
|
$5.21 M
|
$5.77 M
|
$3.25 M
|
$16.01 M
|
$19.88 M
|
$19.27 M
|
$5.58 M
|
$2.44 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$7.72 M
|
$5.02 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$91.96 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.52 M
|
$2.53 M
|
$4.51 M
|
$5.30 M
|
$7.63 M
|
$5.02 M
|
$2.81 M
|
$1.38 M
|
$1.40 M
|
$1.07 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$9.00 K
|
$0.00
|
-$12.00 K
|
-$23.31 M
|
$0.00
|
-$38.24 K
|
-$186.00 K
|
-$416.00 K
|
| Operating Expenses |
$4.89 M
|
$8.06 M
|
$9.71 M
|
$11.06 M
|
$10.86 M
|
-$2.28 M
|
$22.69 M
|
$20.61 M
|
$6.80 M
|
$3.09 M
|
| Cost And Expenses |
$8.85 M
|
$9.30 M
|
$9.72 M
|
$11.06 M
|
$10.87 M
|
-$2.28 M
|
$22.69 M
|
$20.61 M
|
$6.80 M
|
$3.09 M
|
| Interest Income |
$20.00 K
|
$100.47 K
|
$122.68 K
|
$8.10 M
|
$929.00
|
$581.56
|
$8.30 K
|
$1.35 M
|
$5.04 K
|
$14.38 K
|
| Interest Expense |
$359.00 K
|
$1.44 M
|
$7.98 K
|
$5.05 M
|
$3.36 M
|
$348.93 K
|
$4.28 M
|
$3.78 M
|
$20.45 K
|
$100.00
|
| Depreciation & Amortization |
$1.42 M
|
$1.65 M
|
$514.00 K
|
$562.00 K
|
$471.00 K
|
$468.56 K
|
$461.69 K
|
$72.32 K
|
$123.55 K
|
$162.32 K
|
| EBITDA |
-$6.53 M |
-$6.99 M |
-$9.19 M |
-$10.50 M |
-$10.39 M |
$2.75 M |
-$22.21 M |
-$20.54 M |
-$6.67 M |
-$2.93 M |
| EBITDA Ratio |
-4.98
|
-10.62
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-5.75
|
-13.13
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$765.00 K
|
$13.43 M
|
$3.22 M
|
$5.27 M
|
$2.67 M
|
-$3.67 M
|
-$8.93 M
|
-$2.85 M
|
-$3.13 M
|
$704.94 K
|
| Income Before Tax |
-$8.31 M
|
$4.80 M
|
-$6.50 M
|
-$5.80 M
|
-$8.21 M
|
-$1.39 M
|
-$31.62 M
|
-$23.46 M
|
-$9.93 M
|
-$2.38 M
|
| Income Before Tax Ratio |
-6.34
|
7.29
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$8.31 M
|
$4.80 M
|
-$6.50 M
|
-$5.80 M
|
-$8.21 M
|
-$1.39 M
|
-$31.62 M
|
-$23.46 M
|
-$9.93 M
|
-$2.38 M
|
| Net Income Ratio |
-6.34
|
7.29
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.6 |
6 |
-16.8 |
-30.8 |
-80 |
-12.4 |
-1548800 |
-1435800 |
-790280 |
-282320 |
| EPS Diluted |
-3.6 |
6 |
-16.8 |
-30.8 |
-80 |
-12.4 |
-1548800 |
-1435800 |
-790280 |
-282320 |
| Weighted Average Shares Out |
$2.33 M
|
$806.37 K
|
$390.66 K
|
$188.52 K
|
$102.57 K
|
$110.81 K
|
$81.66 K
|
$65.35 K
|
$50.26 K
|
$33.77 K
|
| Weighted Average Shares Out Diluted |
$2.33 M
|
$806.37 K
|
$390.66 K
|
$188.52 K
|
$141.14 K
|
$110.82 K
|
$81.66 K
|
$65.36 K
|
$50.26 K
|
$33.77 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
